I think you are spot on with the comparison between the two....

I think you are spot on with the comparison between the two. From what i understand RAP is able to diagnose a number of lung disease (not including pulmonary embolism) with a great sensitivity and specificity. andvantage of being cheap, easly accessable, non invasive and no ionising radiation to do so (unlike our thechnegas lung scans). However it only provides a binary diagnosis (as far as i understand), yes there is this disease present or no there is non.
The use of Technegas in Ventilation and Prrfusion imaging of the lungs (V/Q scan) allowls the production resonably high quality 3D images that give a whole wealth of information to practitioners. The extent of embolisms/copd with specific localisation, enabling comparison to future/previous scans. Almost every patient diagnosed with a pulmonary embolism will recive a second V/Q scan after a course of medication to ensure that the blood clot has cleared (every scan = 1 PAS set, a positively diagnosed patient uses two PAS sets/ two scans)

Its this advantage that they are trying to higlight in the COPD trials, being able to track the progression of disease and the effects of medication and ultimately using the information to inform not only a diagnosis but guide patient treatment plans.
Exciting times ahead for holders.....as someone onhere has said before and in my opinion this future earnings potential has not been factored in and anything under 1$ will be soon considered a bargan